Pricing Details for Impact BioMedical Inc.'s Initial Public Offering
Impact BioMedical Inc. (NYSE American: IBO) has announced the pricing for its initial public offering (IPO). The company plans to offer 1,500,000 shares, each priced at $3.00. This is a significant step for Impact BioMedical as it prepares to make its debut on the NYSE American Market under the ticker "IBO." Shares are expected to be available for trading shortly.
Closing Process and Underwriter Options
The IPO is set to close soon, provided that all standard closing conditions are met. As part of this offering, Impact BioMedical has given its underwriters a 45-day option to purchase an additional 225,000 shares of common stock on similar terms. All shares in this offering are available directly through Impact BioMedical. Revere Securities, LLC is the book-running manager for this IPO, responsible for overseeing the entire process.
Warrants for Underwriters
In a strategic move to empower its underwriters, Impact BioMedical will issue warrants that permit the purchase of up to 75,000 shares of common stock. If the over-allotment option is fully utilized, this could increase to 86,250 shares. These warrants will allow underwriters to buy shares at 125% of the IPO price and will be valid for exercise from nine months after the IPO until three years afterwards. This reflects the company’s commitment to fostering strong partnerships in the market.
About Impact BioMedical Inc.
Impact BioMedical Inc. is dedicated to discovering, validating, and patenting scientific advancements that pave the way for new healthcare and wellness products. The company actively pursues licensing, co-development, and collaborative opportunities to bring its innovative solutions to market. With a focus on bridging the gap between research and practical health applications, IBO remains committed to advancing the field.
Contact Information for Media and Investors
For media inquiries, please contact Emily Martin at emartin@impactbiomedinc.com. Investors can reach the company directly at info@impactbiomedinc.com.
Frequently Asked Questions
What is the goal of Impact BioMedical's IPO?
The purpose of Impact BioMedical's IPO is to raise funds to further develop and market its innovative healthcare products, aiming to strengthen its industry presence.
When will shares begin trading?
Investors can expect Impact BioMedical shares to start trading on the NYSE American Market shortly after the IPO concludes.
Who manages the IPO underwriting?
Revere Securities, LLC is the appointed book-running manager overseeing the Impact BioMedical IPO.
What options do the underwriters have in this offering?
The underwriters possess a 45-day option to purchase an additional 225,000 shares at the public offering price, enhancing their participation in the IPO.
How does Impact BioMedical bring its innovations to market?
The company partners with licensing organizations, engaging in co-development and joint ventures to successfully market its healthcare innovations.